'This is to inform you that the
At the conclusion of the inspection of the Bengaluru facility, which took place
We will respond to the FDA with a Corrective and Preventive Action Plan (CAPA) and are confident of addressing these observations expeditiously. We remain committed to global standards of Quality and Compliance.'
Contact:
Ms.
Tel: 080 2808 2808
Email: seema.ahuja@biocon.com
(C) 2020 Electronic News Publishing, source